Nvidia Stock Dips After Earnings Why Some Investors Might Be Overlooking the Bigger Picture Patagonias Trademark Lawsuit Against Drag Queen Pattie Gonia Highlights Brand Protection Challenges Markets Reassess Fed Policy Odds After Hot Inflation Data Rate Hike Possibility Emerges CapitaLands 14 Billion Geneo Hub Aims to Strengthen Singapores Life Sciences Ecosystem Meta Shares Slide After Quarterly Report Iran Internet Disruptions Weigh on User Metrics DJI Engages Independent Audit to Address US National Security Concerns Corebridge Financial CRBG Q1 2026 Earnings EPS Misses by a Hair Stock Edges Higher Greenidge Generation Holdings Inc GREE Q1 2025 Earnings Narrowed Loss Beats Estimates as Bitcoin Mining Operations Adjust LPLA Q1 2026 Earnings Marginal EPS Beat Meets a Cautious Market Braemar Hotels Resorts Inc BHR Q1 2026 Earnings Massive EPS Surprise of 42178 Beats Estimates FIS Q1 2026 Earnings EPS Beat Cushions the Blow as Stock Slips NEON Q1 2026 Earnings EPS Misses Estimates Amid Revenue Disclosure Gap MCN Holds Steady at 583 as Premium Income Fund Navigates Narrow Range Palmer Square Capital BDC PSBD Edges Higher as Price Nears Resistance Level Bridger Aerospace Group Holdings Warrants BAERW Hover Near Support Amid Modest Decline Launch One Acquisition Corp LPAA Holds Near Resistance With Modest Gains Innovex International INVX Slips 24 Support Levels Tested After Recent Decline SPHR Q1 2026 Earnings Narrowed Loss Beats Estimates as Sphere Operations Show Promise ELF Q1 2026 Earnings EPS Beat Fails to Lift Stock as Market Digests Mixed Signals ZM Q1 2026 Earnings EPS Beat Drives 9 Stock Surge as Revenue Details Remain Unclear BCTX Q1 2026 Earnings EPS Surprise Beats Estimates Yet Stock Slips 618 RB Global Inc RBA Q1 2026 Earnings Slight EPS Beat Amid Operational Momentum Scully Royalty Ltd SRL Q4 2009 Earnings Massive EPS Surprise of 81934 Highlights Strong Performance SpaceX Scrubs Starship Test Flight Targets Friday Launch for V3 Debut METC Q1 2026 Earnings EPS Misses Estimates Amidst Challenging Market Conditions Acrivon Therapeutics ACRV Edges Higher Biotech Stock Tests Key Resistance at 177